HDV(LOWR-1)におけるリトナビルの有無によるロナファルニブ (LOWR-1)
デルタ型肝炎(HDV)に慢性的に感染した患者におけるリトナビルブーストの有無にかかわらず、ロナファルニブの安全性と有効性を評価するためのオープンラベル、用量範囲、概念実証研究(LOWR-1)
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjects with chronic delta hepatitis will be randomized to receive one of seven different doses of lonafarnib. Dosing will occur over 4-12 weeks, depending on treatment arm, and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the treatment duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of seven dose combinations of lonafarnib with and without ritonavir boosting.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Ankara、トルコ(Türkiye)
- Ankara University Medical School
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Males or females, 18 to 65 years of age who are diagnosed with HDV by PCR
-
Chronic hepatitis D infection, genotype 1, documented by a positive anti-HDV Ab test at least of 6 months duration and detectable HDV RNA by PCR within 3 months to study entry
-
Liver biopsy within the last two years
-
Positive viral load by quantitative PCR
-
Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality and a QT/QTc interval <450 milliseconds - using Bazett's correction
-
Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use one of the following acceptable birth control methods throughout the study:
- abstinence
- surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) six months minimum
- IUD in place for at least six months
- barrier methods (condom or diaphragm) with spermicide
- surgical sterilization of the partner (vasectomy for six months)
- hormonal contraceptives for at least three months prior to the first dose of study drug
-
Willing and able to comply with study procedures and provide written informed consent
Exclusion Criteria:
-
Participation in a clinical trial with or use of any investigational agent within 30 days of Study Visit 1
-
Patients co-infected with HIV
-
Patients with screening tests positive for HCV, or anti-HIV Ab
-
History of decompensated cirrhosis within the past year
-
Active jaundice defined by total bilirubin > 2.0 excluding Gilbert's disease
-
INR ≥ 1.5
-
Eating disorder or alcohol abuse within the past 2 years, excessive alcohol intake (> 20 g per day for females (1.5 standard alcohol drinks) or > 30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) (1.0 fluid oz (US) = 29.57 mL).
-
Drug abuse within the last six months with the exception of cannabinoids and their derivatives
-
Patients with absolute neutrophil count (ANC) < 1500 cells/mm^3; platelet count < 100,000 cells/mm^3; hemoglobin < 12 g/dL for women and < 13 g/dL for men; abnormal TSH,T4, or T3 or thyroid function not adequately controlled; or serum creatinine concentration ≥ 1.5 times upper limit of normal (ULN)
-
History or clinical evidence of any of the following:
- variceal bleeding, ascites, hepatic encephalopathy, CTP score > 6, decompensated liver disease or any other form of non-viral hepatitis
- immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) requiring more than intermittent nonsteroidal anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids (inhaled asthma medications are allowed)
- any malignancy within 3 years except for basal cell skin cancer
- significant or unstable cardiac disease (e.g., angina, congestive heart failure, uncontrolled hypertension, history of arrhythmia)
- chronic pulmonary disease (e.g., chronic obstructive pulmonary disease) associated with functional impairment
- severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization 2
-
Patients with a body mass index > 30 kg/m^2
-
Concomitant drugs known to prolong the QT interval
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:lonafarnib - I
lonafarnib 200 mg BID; n=3 |
antiviral farnesyl transferase inhibitor
他の名前:
|
|
実験的:lonafarnib - II
lonafarnib 300 mg BID; n=3 |
antiviral farnesyl transferase inhibitor
他の名前:
|
|
実験的:lonafarnib - III
lonafarnib 100 mg TID; n=3 |
antiviral farnesyl transferase inhibitor
他の名前:
|
|
実験的:lonafarnib/PEG IFN-a - I
lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3 |
antiviral farnesyl transferase inhibitor
他の名前:
immunomodulator
他の名前:
|
|
実験的:lonafarnib/PEG IFN-a - II
lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3 |
antiviral farnesyl transferase inhibitor
他の名前:
immunomodulator
他の名前:
|
|
実験的:lonafarnib/PEG IFN-a - III
lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=2 |
antiviral farnesyl transferase inhibitor
他の名前:
immunomodulator
他の名前:
|
|
実験的:lonafarnib/ritonavir
lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3 |
antiviral farnesyl transferase inhibitor
他の名前:
CYP 3A4 inhibitor, lonafarnib booster
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy
時間枠:4-12 weeks
|
log HDV RNA decline from baseline to end of treatment (4-12 weeks of lonafarnib-based therapy) |
4-12 weeks
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Cihan Yurdaydin, MD、Ankara University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- EIG-300
- Application #1128309 (その他の識別子:Turkish Regulatory Authority)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。